.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Chubb
US Army
Queensland Health
Merck
Cantor Fitzgerald
Medtronic
Daiichi Sankyo
AstraZeneca

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091623

« Back to Dashboard

NDA 091623 describes THIAMINE HYDROCHLORIDE, which is a drug marketed by Abraxis Pharm, Akorn, Bel Mar, Dell Labs, Fresenius Kabi Usa, Hospira, Luitpold, Mylan Institutional, Parke Davis, Watson Labs, West-ward Pharms Int, and Wyeth Ayerst, and is included in fourteen NDAs. It is available from five suppliers. Additional details are available on the THIAMINE HYDROCHLORIDE profile page.

The generic ingredient in THIAMINE HYDROCHLORIDE is thiamine hydrochloride. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the thiamine hydrochloride profile page.

Summary for 091623

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 091623

Suppliers and Packaging for NDA: 091623

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
THIAMINE HYDROCHLORIDE thiamine hydrochloride INJECTABLE;INJECTION 091623 ANDA General Injectables & Vaccines, Inc 52584-196 52584-196-00 1 VIAL, MULTI-DOSE in 1 BAG (52584-196-00) > 2 mL in 1 VIAL, MULTI-DOSE
THIAMINE HYDROCHLORIDE thiamine hydrochloride INJECTABLE;INJECTION 091623 ANDA Mylan Institutional LLC 67457-196 67457-196-02 25 VIAL, MULTI-DOSE in 1 CARTON (67457-196-02) > 2 mL in 1 VIAL, MULTI-DOSE (67457-196-00)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100MG/ML
Approval Date:Jun 25, 2012TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Teva
Federal Trade Commission
Covington
McKinsey
Fuji
Cantor Fitzgerald
Julphar
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot